Pivalate achieves positive Phase 2 data in brain mets trial
Filed with ASX · · 2 pages · English
• F-18 Pivalate PET shows high uptake regardless of origin of primary tumour • F-18 Pivalate can be used to monitor cerebral metastases • Patients without previous external beam radiation show higher tumour uptake, while those previously treated show a trend towards lower uptake Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmace
Radiopharm Theranostics Limited on 6ix
In the deck
Earlier from Radiopharm Theranostics
- Presentation - Pivalate achieves positive Phase 2 data
- Suspension from Official Quotation
- FDA grants rare pediatric disease designation for DUNP19
- FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma
- RAD Licenses UCLA Dual Action Antibody
Later from Radiopharm Theranostics
- Entitlement Offer to raise up to $10 million
- Successful Completion of Institutional Entitlement Offer
- RAD agreement with NorthStar for supply of Actinium-225
- Entitlement Offer - Extension of Retail Offer
- Security Class Suspension from Quotation RADO
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics